Plasmodium falciparum circumsporozoite vaccine gene optimization for soluble protein expression
US9115205B2 · kind B2 · utility
0Cited by
2References
21Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Oct 18, 2011 |
| Grant date | Aug 25, 2015 |
| Priority date | — |
| Expiry date | Oct 18, 2031 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides novel nucleotide sequence and other constructs used for expression of novel recombinant P. falciparum circumsporozoite proteins in bacterial cells such as E. coli. Processes are provided for producing a soluble recombinant P. falciparum CSP from E. coli. Methods to produce a human-grade, highly immunogenic anti-malaria vaccine based on CSP are shown. The novel recombinant P. falciparum circumsporozoite protein by itself or in combination with other malaria antigens or adjuvants can form the basis of an effective malaria vaccine.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.